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Abstract
Background: Chronic hepatitis C (CHC) Patients, infected with genotype (GT) 2 or 3 are treated with Peg-IFN and
ribavirin (RBV) (800 mg/day) for 24 weeks. Treatment duration can be shortened to 12-16 weeks if a higher dose of
RBV (1.000/1.200 mg/day) was used without considerable loss of responsiveness or increased risk of relapse.
Previously we have shown that in patients with CHC, GT 2/3 RBV can be reduced to 400 mg/day if administered
for 24 weeks without an increase in relapse rates. Therefore we investigated the efficacy of a reduced RBV dosage
of 400 mg/day with shorter treatment duration (16 weeks).
Methods: Treatment naïve patients with CHC, GT 2/3 were randomized to receive 180 μg peginterferona2a/week
in combination with either 800 (group C) or 400 mg/d (group D) for 16 weeks. The primary endpoint was SVR.
Results: 12 months after the first patient was randomized a inferior outcome of group D as compared to group C was
noted, therefore the study was terminated. At study termination 89 patients were enrolled (group C: 31, D: 51). The SVR
rate was statistically different in the two study groups with 51.6% in group C and 28.4% in group D (p = 0.038). Patients
with low viral load had higher SVR rates (C: 67%, D: 33%) than those with high viral load (C: 33%, D: 21%).
Conclusion: Both treatment duration and the dose of RBV play a major role to optimize outcome of patients with
GT3. If one intends to shorten the treatment weight based RBV dose should be used, if lower RBV doses are used
patients should be treated for at least 24 weeks as. A treatment regimen with a reduced RBV dosage and
shortened treatment duration is associated with low SVR rates due to high relapse rates.
Trial registrationNCT01258101
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Background
Chronic hepatitis C is one of the leading causes of
chronic liver disease in Europe. Eight to ten million indi-
viduals suffer from chronic hepatitis C and about 20%
will develop liver cirrhosis and hepatocellular carcinoma
within the next 10-20 years. These individuals would be
in need of liver transplantation [1]. Meanwhile effective
antiviral therapy has become a good option to prevent
end stage liver disease and reduce morbidity and mortal-
ity. Pegylated interferon (PEG-IFN) and ribavirin (RBV)
is the standard of care for chronic hepatitis C. Genotype
has shown to be the most important factor in treatment
outcome [2]. Sustained virological response rates (SVR)
of up to 50% and >75% can be achieved in patients
infected with HCV genotype 1/4, with genotype 2/3,
respectively. For patients infected with genotype (GT) 1 a
treatment course of 48 weeks with combination therapy
(PEG-IFN and RBV 1000-1200 mg/day) is recommended
[3]. Patients infected with genotype 2 or 3 can be treated
with a lower dose of RBV (800 mg/day) for a shortened
duration of 24 weeks without loss of efficacy [4]. Based
on these data treatment guidelines for chronic hepatitis
C recommend the use of a fixed dose of 800 mg/day,
since it is better tolerated and as effective as the 1,000 or
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any medium, provided the original work is properly cited.1,200 mg per day [2]. Treating patients is still a challenge
due to the high rate of adverse events [3,5]. Among the
adverse events of treatment RBV induced haemolytic
anaemia is of particular importance as it accounts for up
to 36% of HCV treatment interruptions, therefore treat-
ment regimes with lover RBV doses and hence better tol-
erated could help to improve tolerability and acceptance
of antiviral treatment [6]. In the era of new antiviral HCV
treatment with direct acting antivirals and additional side
effects like e.g. anaemia it might be important to define
the importance of RBV better.
There are several differences between patients infected
with various genotypes. For example patients with geno-
type 3 typically have a virus induced hepatic steatosis.
Both genotype 2 and 3 patients respond much better
and faster to interferon therapy and have higher SVR
rates (genotype 2 around 90%, genotype 3 around 70%).
The pivotal trial of Hadziyannis [4] clearly showed that
genotype 2/3 patients need less RBV than GT 1 patients.
The reason for this difference is unknown. Several
attempts were made to make treatment more tolerable
in patients with GT 2/3 infection by conducting trials
either to reduce the length of treatment [7], the dose of
PEG-IFN [8] or of RBV. Treatment duration could be
shortened to 12-16 weeks if a higher dose of RBV
(1,000/1,200 mg/day) was used without considerable loss
of responsiveness or increased risk of relapse [7,9,10].
On the other hand we have shown in a randomized,
controlled trial conducted 2003-2006 that in patients
with chronic hepatitis C, genotype 2/3 the dose of RBV
can be reduced to 400 mg/day if treated for 24 weeks
[11] without an increase in relapse rates. Consecutively
the next logical step was to try also to lower the treat-
ment duration to just 16 not 12 weeks, which would
favour a RBV dosage of 1000 mg/day. With the slightly
longer treatment course we hypothesised a reduced RBV
dosage of 400 mg/day would lead to comparable treat-
ment results and matchable relapse rates. The hope was
to further define the role of RBV in patients infected
with genotypes 2/3.
Methods
Criteria for patients being included in the trial were age 18
to 65 years, chronic hepatitis C, HCV genotype 2 or 3
infection, quantifiable HCV RNA in serum (>600 IU/mL
by Cobas Amplicor HCV Monitor Test v.2.0) and elevated
serum ALT activity (>1.5 times the upper limit of normal
[ULN] in the previous 6 months and during screening).
Further inclusion criteria for patients were a haemoglobin
value ≥ 12 g/dL (women) or ≥ 13 g/dL (men), a leukocyte
count >3,000/μL, a platelet count ≥ 100,000/μL, and a
serum creatinine level <1.5 times the ULN. Pre-menopau-
sal women had to have a negative pregnancy test within
24 hours of the first dose. All fertile patients were advised
to use two forms of effective contraception during and
until 6 months after the end of treatment. Patients who
had received prior treatment with IFN or RBV were
excluded. Other exclusion criteria were co-infection with
hepatitis B, immunodeficiency virus, decompensated liver
disease of any cause, coronary heart disease, diabetes mel-
litus requiring insulin therapy, autoimmune disorders,
active alcohol or drug addiction and/or any other unstable
chronic medical condition. Patients on an opiate substitu-
tion therapy were suitable for the trial.
This clinical trial has been reviewed and approved by
the ethics committees from the medical university
Vienna and Elisabethinen Hospital Linz.
Study Protocol
The current study is based on an amendment to a pre-
viously published study comparing two treatment groups:
Group A received 180 μg Peginterferon2a/week in combi-
nation with 800 mg/d of RBV and group B received
180 μg Peginterferon2a/week in combination with
400 mg/d of RBV for a duration of 24 weeks. The protocol
amendment expanded the initial comparison of the groups
A and B by two further treatment groups: 180 μg Peginter-
feron2a/week in combination with either 800 (group C) or
400 mg/d (group D) for 16 weeks. As depicted in the
amendment the randomization for group A as a control
group was continued whereas the randomisation for group
B was terminated. Suitable patients for this study protocol
amendment were randomized 2:2:1 (C: D: A) after enter-
ing a 35-day screening phase. Randomization was per-
formed centrally and was stratified according to HCV
genotype (2 versus 3), baseline HCV RNA level (≤800,000
IU/mL versus >800,000 IU/mL) and study centre. The
ethics committees of all participating study centres
approved the protocol and patients signed a written
informed consent before screening. For safety reasons an
interim analysis was required 12 months after the first
patient was randomized within the amendment. The unfa-
vourable results of this interim analysis prompted an early
termination of the study for ethical reasons. In case of
laboratory abnormalities PEG-IFN dosage could be
reduced from 180 to 135, 90 and 45 μg/week preferably in
a stepwise manner autonomously by the investigator. The
dosage reduction or discontinuation procedure for RBV
concerning haemoglobin values was as follows: values of
>8.5 and <10 g/dL induced a reduction of 200 mg/day;
values of <8.5 g/dL or values <10 g/dL despite four weeks
of treatment at a reduced dosage of 600 mg/day resulted
in discontinuation of RBV. In patients with stable coronary
heart disease any decrease >2 g/dL over a four week per-
iod resulted in a dosage reduction of 200 mg/day. The
dose of RBV could be reduced in 200 mg/day steps in
patients randomized to group D. Any dose reduction
could be reversed to restore the originally assigned dose if
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with PEG-IFN could be administered if RBV was discon-
tinued. However monotherapy with RBV was not per-
mitted. Erythropoietin-stimulation was allowed at
the investigator’s decision if haemoglobin levels fell below
10.5 g/dL.
The primary efficacy end point was sustained virologi-
cal response (SVR), defined as undetectable HCV RNA
(<50 IU/ml) by qualitative PCR assay (Cobas Amplicor
HCV Test v.2.0) after 24 weeks of untreated follow-up
(week 40 or week 48).
Patients in the groups with the shortened treatment
regimen experiencing a relapse in the follow up phase
were offered an off-study retreatment with standard
therapy of 24 weeks PEG-IFN+RBV 800 mg/day. Nonre-
sponders at week 16 were retreated by choice of the
investigator.
Statistical and Analytical Methods
Sample Size Calculation
The original trial comparing 800 mg/d RBV (group A)
with 400 mg/g (group B) [11] for 24 weeks of treatment
assumed response rates of 78% in both treatment groups
with a maximum acceptable difference of 15%. Similar
assumptions for the comparison of group C vs. D
resulted in a planned sample size of 144 patients per
group. The reference group (group A) was continued
with an allocation ratio of 1(group A):2(group C):2
(group D) using a dynamic randomization protocol and
ultimately resulting in a planned sample size of 360
patients in total (A + C + D) for the amendment phase.
A sample size of 244 genotype 3 patients was considered
to be sufficient to compare the sustained response rates
with a power of 80% and a significance level of 5%.
Due to the early termination of the study, the incom-
plete randomization process as well as the stratification
by study centre, genotype and viral load the patients were
unevenly distributed between the study groups (A = 7;
C = 31; D = 51). The use of a dynamic randomization
procedure and the fact that because in the original trial
141 patients have already been randomised to group A
the allocation of patients to the groups C and D in the
beginning of the amendment phase was favoured [12].
Dynamic randomization methods allocate patients to
treatment groups by checking if similar patients were
already randomized, and allocating the next patient to
balance the treatment groups best across all stratification
variables.
Statistical Analysis
For safety reasons an interim analysis was required 12
months after the first patient was randomized within
the amendment phase. Originally the non-inferiority of
PEG-IFN+RBV 800 mg/d versus PEG-IFN+RBV 400
mg/d for 16 weeks should have been investigated but
due to the premature termination of the study for ethi-
cal reasons (see results) the groups were analysed
according to statistical difference using the Fisher’s
exact test. Additional comparison such as baseline char-
acteristics was done using Chi
2-Test for nominal and
using Mann-Whitney-U-Test for quantitative variables.
Due to low numbers the control group (group A) was
not analyzed.
Results
The study groups were comparable in the baseline charac-
teristics age, sex, BMI and route of transmission (Table 1).
The viral load was higher in the group C (1.4 Mio IU/ML)
compared to group D (0.87 Mio IU/mL) but not statisti-
cally significant (p = 0.43). 14 patients terminated treat-
ment early (group C: 7; group D: 7) because of withdrawal
of consent (C = 4, D = 2), drop out (C = 2, D = 3), change
of therapy regimen (C = 1, D = 1), inaccurate randomiza-
tion (D = 1). Premature treatment discontinuation was
higher in patients who acquired HCV infection via intrave-
nous drug usage (IVDU) (46.9% vs. 21.2% in non IVDU).
At an interim analysis 12 months after the first patient
was randomized an inferior outcome of group D (400 mg
RBV/d) as compared to group C (800 mg/d) was noted.
Therefore the study was prematurely terminated for ethi-
cal reasons. At this time 89 patients were already enrolled
(group C: 31, D: 51, control: 7). A flowchart showing all
patients of groups C and D is given in Figure 1.
Efficacy
According to an intention-to-treat analysis the overall
SVR rate in the whole study group was 37.8%. The SVR
rate was statistically different in the study groups with
51.6% in group C and 28.4% in group D (p = 0.038).
The end of treatment response rate (EOT) was 64.5% in
g r o u pCa n d5 6 . 9 %i ng r o u pD .T h er e l a p s er a t eo f
patients who completed follow up was 20% in group C
and 48.3% in group D. Patients with low viral load
(≤800,000 IU/mL) had higher SVR rates (C: 67%, D:
33%) than those with high viral load (>800,000 IE/mL)
(C: 33%, D: 21%).
The SVR rate of those who acquired HCV infection
via IVDU was 32.7% compared to 45.5% in patients
without IVDU history. In group C the SVR rate in
patients without IVDU history was 72.7% compared to
31.8% in group D. The baseline characteristics according
to virological response are presented in Table 2.
Looking only at genotype 3 patients (n = 70), which
were the majority of patients; the SVR rates were similar
to the overall data with a SVR rate of 53.8% in group C
and 29.6% in group D. The relapse rates of patients with
completed follow-up were 17.7% in group C and 48.0%
in group D.
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The two different regimens were well tolerated with
similar adverse event rates in both groups. The most
common adverse events were flu-like syndrome, fatigue
and/or epigastric discomfort which were reported by
70.9% in group C and by 64.7% in group D. Psychiatric
events such as depression were seen by 38.7% in group
C and by 45.1% in group D. Pruritus and/or exanthema
were seen in 25.8% in group C and in 31.4% in group D.
In group C 12.9% experienced hair loss and in group D
13.7%. Thyroid hyper- or hypo function was observed in
6 patients (group C: 1; group D: 5).
The frequency of laboratory abnormalities was compar-
able in both treatment groups. Only the haemoglobin level
was lower in patients receiving RBV 800 mg/day than
those receiving 400 mg/day (see Figure 2). PEG-IFN alfa-2a
was reduced in 16.1% (5 patients) in group C and in 9.8%
(5 patients) in group D. Three of five patients with PEG-
IFN alfa-2a dose reductions in group C achieved SVR
whereas two relapsed and in group D two of five patients
achieved SVR, one patient did not respond to the therapy,
one patient also experiencing a RBV dosage reduction
relapsed and one patient was lost to follow up. In total four
patients received any haematopoietic growth factor. One
patient received erythropoietin, two patients received gran-
ulocyte colony-stimulating growth factor and one patient
received both which was permitted in the study protocol.
There were two reductions in the dosage of RBV which
were surprisingly both conducted in the 400 mg/day treat-
ment group. The two reductions of RBV resulted in one
relapse and one patient was lost to follow up.
Discussion
While reducing RBV dose in patients treated for 24
weeks did not affect the efficacy of treatment [11], the
results of this follow up study indicate that shortened
treatment duration with a reduced RBV dosage is asso-
ciated with lower SVR rates mostly due to high relapse
rates. The results support also the findings of Shiffman
[13] that shortened treatment duration leads to inferior
results. In that study shortening of treatment to 16
weeks was only feasible in patients with low baseline
viral load. While the mean baseline viral load in the pre-
sent study was lower in Group D (400 mg/d RBV) than
in group C (800 mg/d RBV), SVR rates were lower in
Table 1 Baseline characteristics of all randomized patients
Group C
(ribavirin 800 mg)
Group D
(ribavirin 400 mg)
All patients
n3 1 5 1 8 2
Age, years ± SD 36.6 ± 11.0 34.9 ± 9.9 35.5 ± 10.3
Sex, male/female 13/18 21/30 34/48
Mean baseline HCV RNA (Mio. IU/mL) ± SD 1.447 ± 2.93 0.869 ± 1.46 1.083 ± 2.13
Mean Body weight (kg) ± SD 74.2 ± 18.8 68.7 ± 13.9 70.8 ± 16.0
Mean BMI ± SD 24.5 ± 5.7 23.3 ± 3.6
Means by which HCV was acquired, n (%)
Blood transfusion 3 (9.7) 6 (11.8) 9 (11)
Intravenous drug use 20 (64.5) 28 (54.9) 48 (58.5)
Other 3 (9.7) 2 (3.9) 5 (6.1)
Unknown 5 (16.1) 15 (29.4) 20 (24.4)
Figure 1 Patient flow.
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treatment duration in patients receiving RBV dosages
below the recommended dosage is not feasible.
In contrast, Mangia reported that in patients receiving
weight based RBV treatment duration can be shortened
to 12 weeks [7]. Further analysis of predicting factors
allowing treatment shortening revealed that the require-
ments to shorten therapy were a rapid virological
response (RVR), absence of advanced fibrosis, low base-
line viremia, and a low BMI as well as genotype 2
[10,14,15]. Based on our data a RBV dosage of at least
800 mg/day is essential when shortening of treatment is
considered. In case of favourable baseline factors treat-
ment duration can be shortened but if there is need for
RBV dose reduction it is essential for the patient to
undergo the full duration of 24 weeks of antiviral treat-
ment. However, if genotype 2/3 patients achieve RVR a
16 week course of treatment with a weight based RBV
dosage seams equivalent to 24 weeks of treatment with
800 mg/day of RBV [16].
The mechanisms of RBV in treatment of hepatitis C
are still a matter of ongoing discussion. A recent study
suggests that RBV augments the induction of interferon-
stimulated genes in patients treated for HCV infection
[17]. The main effect of RBV is to prevent relapses in
end of treatment responders. However RBV is not the
only factor required for sustained viral elimination,
duration of treatment is also very important. RBV
appears to have little if any effect in the early virologic
response in GT 3 patients [18]. The results of this study
reflect the interplay between of RBV dose and length of
treatment. The recent discovery of IL28B polymorphism
[19-21] has lead to a better understanding of the course
of viral elimination on PEG/RBV therapy. Relapse rates
are substantially lower in C/C patients than in T-allele
carriers. Prolongation of treatment in GT 2/3 patients
was able to decrease relapse rates in T allele carriers
[22]. Thus, in future treatment individualization based
on the IL28B genotype may help to select the best dura-
tion of treatment, as well as the required dose of PEG-
IFN and RBV.
Although the mean haemoglobin level was lower in
patients randomized to 800 mg RBV than to 400 mg
RBV per day the dose reductions were noted only in
group D suggesting that the tolerability cannot generally
be improved by a reduced RBV dosage. The study
results show that adverse event rates do not justify a
reduced RBV dosage since they were comparable in
both groups. However, in a recent study it has been
shown that two functional variants in the inosine tripho-
phastase (ITPA) [23] gene are protective against treat-
ment related anaemia. These genetic biomarkers make
patients more or less sensitive to RBV induced anaemia.
The clinical utility of ITPA genotyping remains unclear,
it may be important in patients with high risk of RBV
associated anaemia or related mortality, but until now
Table 2 Baseline characteristics of patients according to virological response
SVR relapse NR
Mean baseline HCV RNA (Mio IU/mL) 0.76 ± 1.58 1.84 ± 3.28 0.96 ± 0.58
Mean Body weight (kg) ± SD 69 ± 13 76 ± 18 71 ± 8
Mean BMI ± SD 23 ± 4 25 ± 5 24 ± 2
Mean Age, years ± SD 34 ± 9 44 ± 9 50 ± 16
Sex, male/female ± SD 17/14 14/4 1/2
Figure 2 Mean haemoglobin concentration during treatment and follow up.
Maieron et al. BMC Research Notes 2011, 4:220
http://www.biomedcentral.com/1756-0500/4/220
Page 5 of 7there is no evidence that ITPA variants are associated
with the need of RBV dose modifications or treatment
outcome in genotype 2/3 patients [23,24]. Thus, RBV in
the standard dosage is still a backbone of antiviral
therapy.
An important factor contributing to the unfavourable
results was a high proportion of premature treatment dis-
continuation especially in patients who acquired HCV
infection via IVDU (46.9% vs. 21.2%). Adherence rates
range from 37 [25] to 76% and up to one third of patients
is lost to follow up [26] and seem to be somewhat better
than in our cohort. Therefore patients’ selection seems to
be crucial in treating patients with history IVDU another
point might be problems at the less experienced sites
managing these patients [27]. As shown in recent studies
anti HCV treatment is effective in IVDU patients. Base-
line factors associated with lower SVR included
decreased social functioning and current opiate pharma-
cotherapy. Adherent participants were more likely to
achieve SVR (63% vs 29%; P = .025) [28,29]. As shown by
Ebner it is important to select stable patients who are
able to complete therapy but being too strict in the selec-
tion process excludes up to 80% of patients with a fair
chance of being cured but overall SVR rates might be
reduced [30] as high adherence can be achieved in
patients with a history of IVDU [31].
Limitations of the study
The number of patients is small; the study was termi-
nated early because of unfavourable treatment results in
the low RBV group at an interim analysis. Due to the
early termination of the study, the incomplete randomi-
sation process as well as the stratification by study cen-
tre, genotype and viral load the patients were unevenly
distributed between the study groups and this reflects
clearly a limitation of the study. The high proportion of
premature treatment discontinuation in patients who
acquired HCV via IVDU might reflect poor patients’
selection or problems in managing these patients in less
experienced centres.
Conclusion
Both treatment duration and the dose of RBV play a
major role to optimize outcome of patients with GT3. If
one intends to shorten the treatment weight based RBV
dose should be used, if lower RBV doses are used
patients should be treated for at least 24 weeks as. A
treatment regimen with a reduced RBV dosage and
shortened treatment duration is associated with low
SVR rates due to high relapse rates.
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